Return to normal: COVID-19 vaccination under mitigation measures
暂无分享,去创建一个
S. Merler | M. Ajelli | P. Poletti | F. Trentini | G. Guzzetta | V. Marziano | A. Mammone | P. Pezzotti | M. Manica | S. Brusaferro | F. Riccardo | A. Siddu | P. Stefanelli | G. Rezza
[1] N. G. Davies,et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 , 2021, Nature.
[2] C. Aschwanden. Five reasons why COVID herd immunity is probably impossible , 2021, Nature.
[3] Jonathan C. Brown,et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine , 2021, The Lancet.
[4] A. Charlett,et al. Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study) , 2021, SSRN Electronic Journal.
[5] Y. Kreiss,et al. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients , 2021, The Lancet.
[6] C. Viboud,et al. Can a COVID-19 vaccination program guarantee the return to a pre-pandemic lifestyle? , 2021, Research square.
[7] D. Ho,et al. Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 , 2021, bioRxiv.
[8] A. Charlett,et al. Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020 , 2021, medRxiv.
[9] J. Bloom,et al. Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies , 2021, bioRxiv.
[10] T. Blakely,et al. Elimination could be the optimal response strategy for covid-19 and other emerging pandemic diseases , 2020, BMJ.
[11] C. Macintyre,et al. Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia , 2020, Vaccine.
[12] D. Larremore,et al. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus , 2020, Science.
[13] A. Vespignani,et al. Infectivity, susceptibility, and risk factors associated with SARS-CoV-2 transmission under intensive contact tracing in Hunan, China , 2020, medRxiv.
[14] S. Bhatt,et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe , 2020, Nature.
[15] B. Pfefferbaum,et al. Mental Health and the Covid-19 Pandemic. , 2020, The New England journal of medicine.
[16] V. Colizza,et al. A race between SARS-CoV-2 variants and vaccination: The case of the B.1.1.7 variant in France , 2021 .